New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

 

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Follow us on social media for the latest updates in B2B!

Image

Latest

supply chain
Build a Supply Chain That Bounces Back
May 23, 2025

In this episode, Aaron Berg explores how River Logic’s value chain optimization platform empowers businesses to stay agile amid real-world disruptions—from global tariffs to port delays, weather events, and shifting demand. By simulating the financial and operational impact of supply chain decisions in real time, companies can rethink sourcing, pricing, and production strategies to protect…

Read More
tariff
From Tariff Shock to Strategic Advantage
May 23, 2025

In this episode, Aaron Berg reframes tariff disruptions as a strategic opportunity. With River Logic’s value chain optimization solution, companies can quickly model shifts in sourcing, manufacturing, and make-vs-buy decisions to gain a competitive edge. Whether it’s reshoring production or pivoting in response to new trade policies, VCO helps businesses react fast—and capitalize on change…

Read More
tariffs
Tariffs Are Changing—Is Your Supply Chain Ready?
May 22, 2025

Aaron Berg highlights how shifting global tariffs are forcing companies to rethink their entire value chain strategies. With international production, sourcing flexibility, and layered tariff schedules, simple cost assumptions no longer cut it. River Logic’s value chain optimization platform enables leaders to model complex what-if scenarios—like staging production across borders—to find the most cost-effective, compliant…

Read More
markets
The Mechanics of VCO: Modeling Constraints, Costs, and Markets
May 22, 2025

Aaron Berg breaks down how River Logic’s value chain optimization (VCO) engine models the full spectrum of operational and financial variables—from manufacturing constraints to supplier contracts and dynamic market conditions. Unlike traditional models that rely on static costs, VCO captures how costs evolve as decisions change—giving leaders real-time insight into the true financial impact of…

Read More